Clinical trial · Observational
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
Optimizing Prostate Cancer Care: Integrating Risks, Benefits and Patient Experiences in the New Era of Molecular Imaging
NCT06523777CI-TRIAL-00112835PRISMactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Change in Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
- timeFrame
- baseline, 3-6 months, and 12 months
- description
- An 18-item instrument assessing frequency of anxiety in response to prostate cancer with 4 Likert responses ranging from 0 (not at all) to 3 (often); total score range 0 to 54). Higher scores indicate more anxiety.
- measure
- Change in Decisional Conflict Scale (DCS)
- timeFrame
- baseline, 3-6 months, and 12 months
- description
- A 16-item instrument using a 5-point Likert scale, ranging from 0 (strongly agree)-4 (strongly disagree), that has been widely applied to understand decision-making in prostate cancer. Higher scores indicate greater degrees of decisional conflict. DCS subscales include patient perceptions of uncertainty in choosing among treatment options, the contribution of modifiable factors (e.g., feeling uninformed), and effectiveness of decision-making (e.g., satisfaction with the choice). Total and subscale scores range from 0 to 100.
- measure
- Change in Expanded Prostate Cancer Index Composite Short Form (EPIC-26)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Documented diagnosis of prostate cancer * Scheduled for their FIRST PSMA PET scan for prostate cancer * English-speaking * Willing and able to complete 4 surveys electronically or on paper at 3 timepoints (within 1 month after PET scan, 3-6 months, 12 months) * Able to use mobile device (smartphone or tablet) or computer with web access to complete study surveys or able to complete paper surveys Exclusion Criteria: * Lack of access to a mobile device (smartphone or tablet) or computer with web access or unable to receive surveys by mail. * Unable to give consent and be enrolled * PET scan is being conducted within a clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.